New research is shedding light on how weight-loss and diabetes medications like Ozempic, Wegovy, and Mounjaro affect not only ...

Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a ...

Eli Lilly has officially entered the elite $1 trillion market-value club, becoming the first pharmaceutical company to reach ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

While heart disease, diabetes and prediabetes are the most common health concerns related to obesity, many other conditions ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly hit a $1 trillion valuation for the first time, becoming the only healthcare company to reach the milestone as ...

Serena Williams has endorsed GLP-1 medications, raising questions regarding their stigma and performance-enhancing potential for athletes.

(THE CONVERSATION) The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the ...

Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...